Dai Fuhong, Wang Jiangye, An Hongshan, Lei Ting, Tang Ke, Ma Xiaochun, Duo Peng, Ren Pengyun, Chai Wenxiao
Department of Interventional Oncology, Gansu Provincial Hospital Lanzhou, Gansu, China.
Department of Interventional Therapy, Tianzhu County People's Hospital Tianzhu, Gansu, China.
Am J Transl Res. 2019 Jun 15;11(6):3737-3749. eCollection 2019.
The aim of this study was to investigate the efficacy and safety of I particle implantation for treating advanced non-small cell lung cancer (NSCLC).
Data from 56 patients with advanced NSCLC between January 2013 and May 2016 were retrospectively analyzed. The changes of tumor size, objective response rate (ORR), disease control rate (DCR), survival rate of patients and occurrence rate of complications were calculated, and the levels of carcinoembryonic antigen (CEA) and cytokerantin-19-fragment (CYFRA21-1) before and after the treatment were evaluated.
The I particles implantation therapy significantly inhibited the tumor local growth of NSCLC (from 7.75±6.69 to 3.39±2.12 cm) (P<0.001), suggesting a better effectiveness with an RR of 55.4% and DCR of 98.2%. In addition, the I particle implantation down-regulated the CEA expression level of lung adenocarcinoma (LAC) patients (P<0.05). The one-year, two-year, three-year survival rate were 41.1%, 39.3% and 19.6% respectively after the implantation therapy. However, patients implanted I particles had no serious complications except for slight fever.
NSCLC patients at different clinical features all can benefit from the I particle implantation therapy. Moreover, the level of CEA can be used as an efficacy predictor for the I particle implantation therapy for LAC.
本研究旨在探讨碘粒子植入治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。
回顾性分析2013年1月至2016年5月期间56例晚期NSCLC患者的数据。计算肿瘤大小变化、客观缓解率（ORR）、疾病控制率（DCR）、患者生存率及并发症发生率，并评估治疗前后癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA21-1）水平。
碘粒子植入治疗显著抑制NSCLC肿瘤局部生长（从7.75±6.69 cm缩小至3.39±2.12 cm）（P<0.001），RR为55.4%，DCR为98.2%，提示疗效较好。此外，碘粒子植入使肺腺癌（LAC）患者CEA表达水平下调（P<0.05）。植入治疗后1年、2年、3年生存率分别为41.1%、39.3%和19.6%。然而，除轻微发热外，碘粒子植入患者无严重并发症。
不同临床特征的NSCLC患者均可从碘粒子植入治疗中获益。此外，CEA水平可作为LAC碘粒子植入治疗的疗效预测指标。
